✦ LIBER ✦

Immunotherapy for metastatic melanoma

✍ Scribed by Christopher R. Zito; Harriet M. Kluger

Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 118 KB
Volume: 113
Category: Article
ISSN: 0730-2312
DOI: 10.1002/jcb.23402

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Melanoma has traditionally been considered an immunogenic tumor. A number of approaches have been studied for enhancement of antitumor immunity. The first cytokine approved for the treatment of metastatic melanoma, interleukin‐2, has resulted in prolonged responses in a small subset of patients, providing hope that immunotherapy might be useful for this disease. Ipilimumab, a monoclonal antibody to CTLA‐4, was recently approved and a number of other promising investigational approaches are currently being pursued. This manuscript discusses more recent advances in the treatment of melanoma employing a variety of immune‐enhancing approaches. J. Cell. Biochem. 113: 725–734, 2012. © 2011 Wiley Periodicals, Inc.

📜 SIMILAR VOLUMES

Adjuvant immunotherapy for melanoma

✍ L. J. Humphrey; S. Taschler-Collins; P. M. Coldfarb; O. Sincla; F. J. Volenec 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 282 KB

Adjuvant immunotherapy was administered to 84 lymph-node-negative and 25 lymph-node-positive melanoma patients. This active specific homologous cell protein preparation was given after aggressive surgery and given over 2 years. Projected and observed survival rates are presented as well as other cli

Surgery for metastatic melanoma

✍ Sonya M. Sharpless; Tapas K. Das Gupta 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 48 KB 👁 2 views

The appearance of distant metastases in a patient with malignant melanoma usually prophesies an early death: median survival is only 5 to 8 months. Surgery definitely can palliate certain patients and lead to a prolongation of life for others. In selected surgical candidates, an isolated nonvisceral

Adjuvant Immunotherapy for patients with

Adjuvant Immunotherapy for patients with melanoma

✍ Jeffrey N. Myers 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 29 KB 👁 2 views

Adjuvant immunotherapy with transfer fac

Adjuvant immunotherapy with transfer factor in patients with melanoma metastatic to lung

✍ Raymond L. Gonzalez; Peter Wong; Lynn E. Spitler 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 English ⚖ 686 KB

Overview of melanoma vaccines: Active sp

Overview of melanoma vaccines: Active specific immunotherapy for melanoma patients

✍ David W. Ollila; Mark C. Kelley; Guy Gammon; Donald L. Morton 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 2 views

Although a phase III trial has yet to show a statistically significant improvement in the disease-free or overall survival of melanoma patients receiving vaccine therapy, several phase II trials have shown enhanced disease-free and overall survival of patients who develop a humoral and/or cellular r

Immunotherapy of metastatic kidney cance

Immunotherapy of metastatic kidney cancer

✍ Giancarlo Pizza; Caterina De Vinci; Giuseppe Lo Conte; Paolo Maver; Ennio Dragon 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 337 KB

122 MRCC patients were treated by monthly intralymphatic injections (containing a mean of 573 IL-2 U and 26 ؋ 10 6 LAK cells) and i.m. administration of IFN and TF; 71 patients also received a 3-day cycle of monthly IL-2 inhalations with a mean of 998 daily U. MRCC cases not treated by immunotherapy